Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

Fig. 2

Correlation between somatic mutations and clinical responses. a Landscape of mutations detected in 88 patients at enrollment. Each row represents a gene, and each column corresponds to a participant in the study. The number of patients with mutations is listed on the left. Bar plots indicate the number of mutations per patient (top bar plot) and the number of mutations detected for each gene (side bar plot). b Co-mutations among the 88 patients with gene mutation detection. The thickness of the connecting lines indicates the frequency with which the two mutations co-occurred. c Landscape of mutations detected in 88 patients at enrollment, according to whether the patient achieved a response (complete remission or complete remission with incomplete count recovery) or not. Each row represents a gene, and each column corresponds to a participant in the study. CEBPA-dm, CEBPA double mutation

Back to article page